Gene Therapy for Overactive Bladder, Incontinence Shows Good Safety, Efficacy
The locally injected gene therapy product is the subject of an ongoing phase 2a clinical trial.
CYAD-211 Induces Favorable Safety, Supports Proof of Concept in Patients With Relapsed/Refractory Myeloma
Safety and the recommended dose of CYAD-211 and the lymphodepletion regimen served as the primary end point of the study.
Beti-Cel Induces Transfusion Independence in Patients With β-thalassemia
The findings, which were simultaneously reported in the New England Journal of Medicine, support beti-cel as a potentially curative, one-time treatment option for these patients.
Longer Follow-Up Shows Cilta-Cel Induces Deep, Durable Responses in Relapsed/Refractory MM
At the 18-month follow-up, the CAR T-cell therapy led to early, deep, and durable responses with a manageable safety profile in patients with relapsed/refractory multiple myeloma.
Ide-Cel Demonstrates Durable Responses in Relapsed/Refractory Multiple Myeloma
The CAR T-cell therapy idecabtagene vicleucel continues to demonstrate improved survival among heavily pretreated patients with relapsed/refractory multiple myeloma.
Stem Cell Recipients Develop Robust Immunity Against SARS-CoV2 and Common Human Coronaviruses
These findings may have implications for patients with hematologic malignancies, suggesting the development of protective memory against SARS-CoV2 and non-SARS human coronaviruses.
FDA Approves Selpercatinib for 3 RET-Positive Cancer Types
The FDA approved the first therapy to treat cancers with rearranged during transfection (RET) gene alterations.
CAR T-Cell Therapy Shows Promise in Multiple Hematologic Malignancies
FDA Grants Breakthrough Therapy Designation to Abatacept for Acute GVHD Prevention
The FDA granted a breakthrough therapy designation to abatacept for the prevention of moderate to severe acute graft-versus-host disease in hematopoietic stem cell transplants from unrelated donors.
CAR T-Cell Therapy Studies to Look for at the ASH Annual Meeting
Research on chimeric antigen receptor T-cell therapy to be presented at the ASH Annual Meeting & Exposition is set to address drawbacks associated with treatment.
Proof-of-Concept Study of CAR-NK Cell Therapy with Engineered Persistence Shows Potential
Robert A. Brodsky, MD discussed the study of a first-of-kind multi-antigen targeted off-the-shelf chimeric antigen receptor- natural killer cell therapy with engineered persistence that will be presented at the ASH Annual Meeting & Exposition.
First HCT Following CAR T-Cell Therapy Reduces Risk for ALL Relapse
Receiving a stem cell transplant for the first time following CD19 CAR T-cell therapy induced a reduction in the risk for acute lymphoblastic leukemia (ALL) recurrence, according to a retrospective analysis of the phase I/II PLAT-02 study.
Lurbinectedin Combo Induces Clinical Activity in Chemo-Sensitive SCLC
Lurbinectedin plus doxorubicin demonstrated significant clinical activity as a second-line therapy for patients with small cell lung cancer, especially when excluding refractory patients.
FT819 Derives Renewable, Reproducible Process of CAR T-Cell Therapy
An off-the-shelf, dual-targeted chimeric antigen receptor T-cell approach yielded positive results in preclinical specificity, functionality, and efficacy studies.
2 Clarke Drive Cranbury, NJ 08512